Member of Congress ‘flies out’ to Nanoscope Therapeutics

Written By Kathleen Otto

Rep. Jake Ellzey (R-TX) delved into the forefront of biomedical innovation during his recent "fly-out" to Nanoscope Therapeutics, a leading biotech company headquartered in Arlington, TX. Nanoscope, a late-stage clinical biotech, specializes in developing transformative gene therapies aimed at combating genetic diseases causing vision impairment and blindness.

During his visit, Rep. Ellzey engaged with Nanoscope's CEO, Sulagna Bhattacharya, and gained firsthand insights into the company's pioneering work. Of particular note was Nanoscope's breakthrough treatment, MCO-010, which recently demonstrated remarkable efficacy in a Phase 2 clinical trial for advanced retinitis pigmentosa (RP). This achievement, coupled with Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA), highlights the potential of Nanoscope's therapies to address critical unmet medical needs.

Kathleen Otto
Previous

Janssen-Cilag, a Johnson & Johnson company, Receives CHMP Nod for RYBREVANT® in First-Line NSCLC Treatment with EGFR Exon 20 Insertion Mutations
Next

Medtronic's Inceptiv™ Closed-Loop Spinal Cord Stimulator Receives FDA Approval for Chronic Pain Treatment